1 tion-dependently self-administered vaporized sufentanil.

2 onse (nosepoke) to receive 10 s of vaporized sufentanil, a potent opioid, in 2 h daily sessions.

3 otentials (LFP) in primary visual cortex, in sufentanil-anaesthetized marmoset monkeys.

4 nventional fentanyl such as ohmefentanyl and sufentanil and discover the pattern of THz spectra of fe

5 escalation baseline levels of responding for sufentanil and mechanical sensitivity.

6 during sedation with continuous infusions of sufentanil and midazolam.

7 romorphone, oxycodone, tapentadol, fentanyl, sufentanil, and remifentanil) obtained from the Federal

8                                        Serum sufentanil concentrations significantly correlated with

9         Exposure to the potent full agonists sufentanil, dihydroetorphine, etorphine, etonitazine, an

10 not short access (ShA; 1 h/day) to vaporized sufentanil escalated their drug intake over time and exh

11 ophylactic vaccination reduced fentanyl- and sufentanil-induced antinociception, respiratory depressi

12 istate 13-acetate (PMA), not only attenuates sufentanil inhibition of evoked cAMP formation but rever

13 pioid inhibition to enhancement and restores sufentanil inhibitory responsiveness.

14 at the mu-selective opiate receptor agonist, sufentanil, produces a naloxone-reversible, concentratio

15 erical Rating Scale and cumulative dosage of sufentanil to grade pain during the first 48 h.

16  significantly correlated with the number of sufentanil vapor deliveries.

17  These findings demonstrate that the operant sufentanil vapor self-administration model has both face

18  (ie, after the return to extended access to sufentanil vapor), LgA rats again developed naloxone-pre

19 d receptors in the reinforcing properties of sufentanil vapor.

20                                              Sufentanil was universally employed for intraoperative a

21 ted a significant increase in responding for sufentanil when given the preferential mu-opioid recepto